Rohto Pharmaceutical Co Ltd
TSE:4527

Watchlist Manager
Rohto Pharmaceutical Co Ltd Logo
Rohto Pharmaceutical Co Ltd
TSE:4527
Watchlist
Price: 2 501.5 JPY 0.3% Market Closed
Market Cap: 590.8B JPY

Rohto Pharmaceutical Co Ltd
Long-Term Debt

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Rohto Pharmaceutical Co Ltd
Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Rohto Pharmaceutical Co Ltd
TSE:4527
Long-Term Debt
ÂĄ42B
CAGR 3-Years
49%
CAGR 5-Years
52%
CAGR 10-Years
44%
Shiseido Co Ltd
TSE:4911
Long-Term Debt
ÂĄ224.8B
CAGR 3-Years
-3%
CAGR 5-Years
14%
CAGR 10-Years
9%
Kao Corp
TSE:4452
Long-Term Debt
ÂĄ191.5B
CAGR 3-Years
4%
CAGR 5-Years
-3%
CAGR 10-Years
5%
Kose Corp
TSE:4922
Long-Term Debt
ÂĄ8B
CAGR 3-Years
43%
CAGR 5-Years
63%
CAGR 10-Years
32%
F
Fancl Corp
TSE:4921
Long-Term Debt
ÂĄ0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Kobayashi Pharmaceutical Co Ltd
TSE:4967
Long-Term Debt
ÂĄ394m
CAGR 3-Years
-1%
CAGR 5-Years
-7%
CAGR 10-Years
-5%
No Stocks Found

Rohto Pharmaceutical Co Ltd
Glance View

Market Cap
565.2B JPY
Industry
Consumer products

Rohto Pharmaceutical Co Ltd., a company deeply rooted in the legacy of Japanese innovation, traces its beginnings to the late 19th century. Initially specializing in over-the-counter (OTC) medicines, it has adeptly expanded its reach to include skincare and healthcare products. The company’s journey from its inception was marked by a relentless pursuit of addressing the evolving needs of its consumer base, leveraging its expertise in pharmaceuticals and chemistry to create products that cater to health and wellness. Rohto's commitment to research and development has enabled it to pioneer unique formulations, effectively blending traditional practices with modern scientific advances. This strategy has allowed Rohto to establish a strong foothold not only in Japan but also in international markets, appealing to a broad demographic. The core of Rohto's business lies in its ability to commercialize its innovative solutions across various channels. The company generates revenue primarily through the sale of its diversified product lines, which include eye drops, dermatological creams, and other personal care products. Rohto’s strategic acquisitions and partnerships have also played a critical role in its growth, enabling it to expand its market presence and adapt to global health trends. The ability to anticipate and respond to consumer needs allows Rohto to maintain a robust product pipeline, ensuring consistent sales performance. Through its global distribution networks and focused marketing efforts, Rohto capitalizes on its brand reputation for quality and reliability, ensuring a steady stream of profits.

Intrinsic Value
2 468.92 JPY
Overvaluation 1%
Intrinsic Value
Price

See Also

What is Rohto Pharmaceutical Co Ltd's Long-Term Debt?
Long-Term Debt
42B JPY

Based on the financial report for Jun 30, 2025, Rohto Pharmaceutical Co Ltd's Long-Term Debt amounts to 42B JPY.

What is Rohto Pharmaceutical Co Ltd's Long-Term Debt growth rate?
Long-Term Debt CAGR 10Y
44%

Over the last year, the Long-Term Debt growth was 117%. The average annual Long-Term Debt growth rates for Rohto Pharmaceutical Co Ltd have been 49% over the past three years , 52% over the past five years , and 44% over the past ten years .

Back to Top